Moderna Accelerates Pipeline: Expanded Partnership with CEPI Offers Strategic Opportunities for Investors
Reading Time: 2 minutes
Moderna receives up to $50 million from CEPI for vaccine development against the Bundibugyo Ebola virus. The established mRNA platform enables rapid clinical testing as well as parallel production. The increasing pipeline diversification strengthens growth and reduces future revenue fluctuations. Expansion of Strategic Collaborations On June 1, Moderna announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI). In this context, the company focuses on a vaccine against the Bundibugyo Ebola virus...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
